MX2023012958A - Compuestos y metodos anticonceptivos. - Google Patents

Compuestos y metodos anticonceptivos.

Info

Publication number
MX2023012958A
MX2023012958A MX2023012958A MX2023012958A MX2023012958A MX 2023012958 A MX2023012958 A MX 2023012958A MX 2023012958 A MX2023012958 A MX 2023012958A MX 2023012958 A MX2023012958 A MX 2023012958A MX 2023012958 A MX2023012958 A MX 2023012958A
Authority
MX
Mexico
Prior art keywords
methods
formula
compounds
compound
contraceptive compounds
Prior art date
Application number
MX2023012958A
Other languages
English (en)
Spanish (es)
Inventor
Ingrid Gunda Georg
Narsihmulu Cheryala
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of MX2023012958A publication Critical patent/MX2023012958A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2023012958A 2021-05-04 2022-05-03 Compuestos y metodos anticonceptivos. MX2023012958A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163184014P 2021-05-04 2021-05-04
US202263307943P 2022-02-08 2022-02-08
US202263326524P 2022-04-01 2022-04-01
PCT/US2022/027506 WO2022235693A1 (en) 2021-05-04 2022-05-03 Contraceptive compounds and methods

Publications (1)

Publication Number Publication Date
MX2023012958A true MX2023012958A (es) 2024-01-05

Family

ID=81854578

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012958A MX2023012958A (es) 2021-05-04 2022-05-03 Compuestos y metodos anticonceptivos.

Country Status (9)

Country Link
US (3) US11780828B2 (https=)
EP (1) EP4334309A1 (https=)
JP (1) JP7828661B2 (https=)
KR (1) KR20240004737A (https=)
AU (1) AU2022270088A1 (https=)
CA (1) CA3217096A1 (https=)
IL (1) IL308171A (https=)
MX (1) MX2023012958A (https=)
WO (1) WO2022235693A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7828661B2 (ja) * 2021-05-04 2026-03-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 避妊薬の化合物及び方法
WO2025251031A1 (en) * 2024-05-30 2025-12-04 Yourchoice Therapeutics, Inc. Contraceptive compounds and dosing for the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
CN1255396C (zh) * 1996-03-18 2006-05-10 卫材株式会社 含有稠环的羧酸衍生物
US7105566B2 (en) * 2002-10-22 2006-09-12 Allergan, Inc. Methods of treatment during vascular procedures
AU2015365738B2 (en) * 2014-12-19 2020-07-23 Galderma Research & Development Novel compounds, synthesis method thereof and use of same in medicine and in cosmetics
WO2017201200A1 (en) * 2016-05-19 2017-11-23 Orphagen Pharmaceuticals, Inc. Therapeutic compositions containing rar-alpha antagonists
WO2019014468A1 (en) * 2017-07-13 2019-01-17 Io Therapeutics, Inc. RECEPTOR SUBTYPE AND RETINOID COMPOUNDS AND SELECTIVE REXINOIDS OF A FUNCTION IN COMBINATION WITH IMMUNE MODULATORS FOR ANTICANCER IMMUNOTHERAPY
EP3709990A4 (en) * 2017-11-17 2021-12-01 The Regents of the University of California MANIPULATION OF THE RETIC ACID SIGNAL PATH
JP7828661B2 (ja) * 2021-05-04 2026-03-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 避妊薬の化合物及び方法

Also Published As

Publication number Publication date
US20250276962A1 (en) 2025-09-04
US20220388993A1 (en) 2022-12-08
US12281105B2 (en) 2025-04-22
AU2022270088A1 (en) 2023-11-23
EP4334309A1 (en) 2024-03-13
KR20240004737A (ko) 2024-01-11
CA3217096A1 (en) 2022-11-10
JP7828661B2 (ja) 2026-03-12
IL308171A (en) 2023-12-01
JP2024516023A (ja) 2024-04-11
US11780828B2 (en) 2023-10-10
US20240109872A1 (en) 2024-04-04
WO2022235693A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
MX2021008358A (es) Lipidos para la administracion de agentes activos en nanoparticulas lipidicas.
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
CL2019003669A1 (es) Inhibidores de quinasa alk2 que contienen imidazol.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
PE20241068A1 (es) Moduladores de profarmacos de la via de estres integrada
CY1119357T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν συνδετες υποδοχεων σιγμα
CO2020014677A2 (es) Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes
CO2022017622A2 (es) Inhibidores de quinasa nek7
CL2022000802A1 (es) Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
CR20230115A (es) Compuestos heterocíclicos
CO2023014204A2 (es) Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7)
MX2024007904A (es) Compuestos y uso de estos como inhibidores de hdac6.
UY39625A (es) Derivados tricíclicos útiles como inhibidores de parp7
CL2021002621A1 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
MX2023012958A (es) Compuestos y metodos anticonceptivos.
CL2019001023A1 (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
CO2022019131A2 (es) Inhibidores de la quinasa nek7
UY26564A1 (es) Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
CO2024001017A2 (es) Compuestos terapéuticos y procedimientos
MX2023006176A (es) Nuevos derivados de indazol acetileno.
UY31854A (es) Derivados sustituidos de 3-oxo-isoindolin-1- carboxamidas n-sustituidas y aplicaciones
CO2026000093A2 (es) Composiciones farmacéuticas para inhibidores de la cinasa nek7
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria